Graft Polymer (UK) PLC ( (GB:SVNS) ) has provided an update.
Solvonis Therapeutics plc has announced progress in its AWKN-SDN-14 program, a collaboration with Awakn Life Sciences Corp. aimed at developing a novel drug for PTSD. The program, which seeks to enhance social bonding and neurotransmitter activity, has overcome disruptions in candidate synthesis and is now on track with Evotec SE appointed for key preclinical testing. This advancement underscores Solvonis’ commitment to addressing mental health disorders and could significantly impact PTSD treatment options.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, with a particular emphasis on trauma-related conditions such as PTSD. The company aims to improve outcomes for individuals suffering from these disorders, estimating a current affected population of 20 million across the U.S., UK, and key EU markets.
YTD Price Performance: -24.00%
Average Trading Volume: 11,457,575
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £3.73M
See more insights into SVNS stock on TipRanks’ Stock Analysis page.